Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes

Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by clonal hematopoiesis, recurrent genetic abnormalities, myelodysplasia, and a risk of progression to acute myeloid leukemia (AML) [ 1 , 2 , 3 ]. Despite the availability of various therapeutic interventions such as chemotherapy and hypomethylating agents (HMAs) to delay disease progression, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy [ 1 ].